Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for its animal health business Merial – the latest in a trend for multi-billion swaps in big pharma. The deal ...

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.

Ingelheim, Germany, 22 May 2025 – Boehringer Ingelheim today announced that new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRP α) innate immune ...

Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat generalised pustular psoriasis (GPP) flares.

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc.

About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, ...

TOKYO -- German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base ...

The site was created by Boehringer Ingelheim after a survey identified knowledge gaps among owners on many health topics ...

Boehringer Ingelheim has launched Vetmedin (pimobendan) 1.5 mg/ml oral solution for dogs in the UK, offering a new treatment ...

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...